Eli Lilly’s COVID-19 antibody drug gets interim authorization in Canada
Health Canada has issued emergency authorization to Eli Lilly’s COVID-19 treatment bamlanivimab, which was developed in partnership with Canadian biotech company AbCellera. The move follows the United States Food & Drug Administration (FDA) also issuing emergency authorization. The drug is meant as an intervention when a high-risk person is first diagnosed with COVID-19 in hopes of preventing disease progression and avoiding hospitalization. The drug, a monoclonal antibody that copies antibodies found in humans, has shown signs of reducing progression to more severe disease in trials of mild to moderate COVID-19 outpatients, resulting in the emergency authorization.
Published: November 22, 2020
CBC NewsRead Article